Here’s what you should know:
1. Synergy Pharmaceuticals filed for chapter 11 bankruptcy Dec. 12. Bausch plans to pay approximately $200 million to acquire the assets.
2. Bausch will serve as a “stalking horse” bidder in a court-supervised auction and sale as Synergy sells off its assets. In this process, Bausch agreed to acquire most of Synergy’s assets and offer select employees positions within Bausch.
3. Bausch has particular interest in Synergy’s Trulance, which compliments Bausch’s Xifaxan. Trulance is an irritable bowel syndrome with constipation treatment, while Xifaxan is an irritable bowel syndrome with diarrhea treatment.
4. Bausch Health will also acquire Synergy’s pipeline candidate dolcanatide, an ulcerative colitis drug.
More articles on gastroenterology:
Internists file antitrust suit against American Board of Internal Medicine’s maintenance of certification program — 6 insights
GI researcher Dr. Anil Rustgi named director of Herbert Irving Comprehensive Cancer Center
How a New Orleans clinic raised its CRC screening rates from 3% to 80% in just 6 years
